Effects of (S)-ketamine on depression-like behaviors in a chronic variable stress model: a role of brain lipidome
Cui-Hong Zhou, Xinxin Zhao, Xinxu Ma, Hongzhe Ma, Rui Li, Guangtao Hu, Hua-ning Wang, Z. Peng, Min Cai
Frontiers in Cellular Neuroscience February 15, 2023 DOI: 10.3389/fncel.2023.1114914 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled experiment Peer reviewed |
|---|---|
| Population | Mice |
| Intervention | (S)-ketamine |
| Dose | single sub-anesthetic dose |
| Topics | Depression Esketamine Ketamine |
| Key findings | (S)-ketamine partially normalized stress-induced lipid disturbances in the hippocampus, correlating with reversal of depressive-like behaviors in mice. |
Abstract
Introduction: Compelling evidence indicates that a single sub-anesthetic dose of (S)-ketamine elicits rapid and robust antidepressant effects. However, the underlying mechanisms behind the antidepressant effects of (S)-ketamine remain unclear.
Methods: Here, using a chronic variable stress (CVS) model in mice, we analyzed changes inthe lipid compositions of the hippocampus and prefrontal cortex (PFC) with a mass spectrometry-based lipidomic approach.
Results: Similar to previous research outcomes, the current study also showed that (S)-ketamine reversed depressive-like behaviors in mice produced by CVS procedures. Moreover, CVS induced changes inthe lipid compositions of the hippocampus and PFC, notably in the contents of sphingolipids, glycerolipids, and fatty acyls. With the administration of (S)-ketamine, CVS-induced lipid disturbances were partially normalized, particularly in the hippocampus.
Conclusion: Altogether, our results indicated that (S)-ketamine could rescue CVS-induced depressive-like behaviors in mice through region-specific modulation of the brain lipidome, contributing to the understanding of (S)-ketamine’s antidepressant effects.
Comparable studies
Other preclinical and animal studies on ketamine for depression, most cited first.